Koji Kameyama
Papers
1
Total Citations
6
H-Index
1
About
Dr. Koji Kameyama is a cancer geneticist whose research focuses on the molecular mechanisms driving renal cell carcinoma, particularly the role of chromosomal instability and the Von Hippel-Lindau (VHL) tumor suppressor pathway. His most cited work, a 2022 study on multifocal clear cell renal cell carcinoma (ccRCC), reveals how derivative chromosome 3 loss from a t(3;6)(q12;q14) translocation, followed by differential VHL mutations, underlies the development of multiple, genetically distinct tumors within the same kidney. This finding provides critical insight into the clonal evolution and heterogeneity of ccRCC, demonstrating that early chromosomal events can set the stage for diverse VHL inactivation patterns. With 6 citations, this paper has already garnered attention for its implications in understanding tumor multifocality and treatment resistance. Dr. Kameyama’s contributions are particularly valuable for researchers studying VHL biology, renal cancer genomics, and the interplay between structural chromosomal aberrations and point mutations in tumorigenesis. His work underscores the importance of dissecting the sequence of genetic events that drive cancer progression, offering a clearer roadmap for future therapeutic strategies targeting the VHL-HIF axis.
Research Focus
Key Achievements
Top Papers
- 1